Consulting Reports

Many of the studies OHE Consulting performs are proprietary and the results are not released publicly. Studies of interest to a wide audience, however, may be made available, in whole or in part, with the client’s permission. They may be published by OHE alone, jointly with the client, or externally in scholarly publications.

The following examples of recent OHE Consulting projects are limited to those with publicly available materials that may be downloaded from this website.

Besley, S., Henderson, N., Towse, A. & Cole, A. 

Consulting Report
June 2022

Gene therapies represent a new era of medicine, offering the potential for truly transformational health gains, and further benefits for society and health systems. Gene therapy is particularly relevant to rare disease patients, as more than 80 per cent of rare diseases have a known monogenic (single gene) cause. In contrast to traditional small molecule medicines, gene therapies have the potential to correct underlying genetic defects, offering the potential for transformational health gains rather than simply managing symptoms.

Cookson, G. and Hitch, J.

Consulting Report
June 2022

In recent years, U.S. policymakers have been considering reforms to tackle high and rising prescription drug spending, including unprecedented direct limits on prices and price growth for top-selling medicines. By affecting expected prices and revenues, this type of reform will impact biopharmaceutical companies’ incentives to innovate. However, the magnitudes and timings of impacts on the numbers of new drugs coming to market are unclear.

Mott, D., Schirrmacher, H. & Garau, M. 

Consulting Report
March 2022

Generic preference-based measures are often used for capturing patients’ health-related quality of life (QOL) to assess quality-adjusted life years (QALYs) in health technology assessment (HTA). Whilst this type of measure, which includes commonly used EQ-5D instruments, are useful for enabling comparability between assessments, they might not always capture all the dimensions of QOL that are important to patients.

Brogaard, N., Abdul-Ghani, R., Bayle, A.,  Henderson, N.,  Bréant, A, and Steuten, L.

Consulting Report
January 2022

A paradigm shift is occurring in cancer care with the introduction of tumour-agnostic therapies, for which the indication is defined by the molecular signature of the tumour rather than by its location. Several agents have already gained regulatory approval, including pembrolizumab for solid tumours with high microsatellite instability (MSI-H) or high tumour mutational burden (TMB-H), and larotrectinib and entrectinib for neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours, and many other emerging molecules are set to enter the market over the next decade.

Brassel S., Neri M., Schirrmacher H., and Steuten L.

 

Consulting Report
October 2021

The NHS is facing unprecedented health system pressure, with a record number of patients waiting for care, while their underlying condition is potentially worsening due to exceptionally long waits.

When there is excess demand for health care, treating one patient means losing the opportunity to treat another. These opportunity costs demonstrate the need to consider health system capacity value, one of the so-called "broader value elements" that is often not fully captured in traditional value assessments.